Calithera Biosciences, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other diseases. Its lead product candidate, CB-839, targets glutaminase, which is critical for the growth of certain tumors, particularly in renal cell carcinoma. The company operates primarily in the United States, leveraging its proprietary drug discovery platform to identify and develop new treatments.
Calithera generates revenue primarily through partnerships and collaborations with larger pharmaceutical firms, which provide funding for the development of its drug candidates. The company has a strong pipeline, which includes both preclinical and clinical-stage assets, allowing it to leverage its proprietary technology in drug discovery.
Clinical trial results for CB-839, particularly in renal cell carcinoma
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or setbacks for drug candidates
Market sentiment around the biotechnology sector
Regulatory changes that could impact drug approval processes
Technological disruptions in drug discovery and development
Emerging therapies targeting similar pathways as CB-839
Increased competition from larger pharmaceutical companies with more resources
High cash burn rate with no current revenue generation
Potential dilution of equity if additional funding is required
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for biotech firms, affecting their ability to fund R&D and clinical trials, but the impact is less pronounced given the company's low debt levels.
minimal - With a debt/equity ratio of 0.08, Calithera is not heavily reliant on credit markets.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has experienced significant volatility, particularly around clinical trial results and regulatory announcements.